Skip to main content
Top
Published in: Annals of Surgical Oncology 7/2014

01-07-2014 | Gynecologic Oncology

Survival Impact of Lymphadenectomy Stratified by Nodal Metastatic Probability in Endometrial Cancer

Authors: Martin Koskas, MD, Marie Fournier, MD, Dominique Luton, MD, Emile Darai, MD, Roman Rouzier, MD

Published in: Annals of Surgical Oncology | Issue 7/2014

Login to get access

Abstract

Background

Our objective was to identify a subgroup of patients with early-stage endometrial cancer in whom lymphadenectomy was associated with enhanced survival based on the stratification of lymph node (LN) metastasis probability provided by a previously developed nomogram.

Methods

Data from the Surveillance, Epidemiology, and End Results database for 66,210 patients with histologically proven endometrial cancer were analyzed. For each patient, the LN metastasis probability according to the previously developed nomogram was calculated. Patients were clustered into quintiles according to their LN metastasis probability. The cancer related survival in each quintile group was calculated using Kaplan–Meier analysis and compared based on whether patients underwent lymphadenectomy.

Results

Except for the second quintile group, the specific survival rate systematically decreased when the predicted LN probability increased. In the five quintile groups, the 5-year specific survival rate was significantly higher in the patients who did not undergo lymphadenectomy compared with those who underwent lymphadenectomy and had ≥10 or <10 LNs removed.

Conclusions

Our results suggest the pejorative outcome associated with a higher risk of LN metastasis is not counterbalanced by the lymphadenectomy.
Literature
1.
go back to reference Bendifallah S, Genin AS, Naoura I, et al. A nomogram for predicting lymph node metastasis of presumed stage I and II endometrial cancer. Am J Obstet Gynecol. 2012;207:197 e1–8.PubMed Bendifallah S, Genin AS, Naoura I, et al. A nomogram for predicting lymph node metastasis of presumed stage I and II endometrial cancer. Am J Obstet Gynecol. 2012;207:197 e1–8.PubMed
2.
go back to reference Koskas M, Chabbert-Buffet N, Bendifallah S, Luton D, Clavel-Chapelon F, Rouzier R. Prognostic value of the 2009 FIGO staging for endometrial cancer: an illustration of the E3N cohort. Int J Gynecol Cancer. 2012;22:447–51.PubMedCrossRef Koskas M, Chabbert-Buffet N, Bendifallah S, Luton D, Clavel-Chapelon F, Rouzier R. Prognostic value of the 2009 FIGO staging for endometrial cancer: an illustration of the E3N cohort. Int J Gynecol Cancer. 2012;22:447–51.PubMedCrossRef
3.
go back to reference Hoekstra AV, Kim RJ, Small W Jr, et al. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes. Gynecol Oncol. 2009;114:273–8.PubMedCrossRef Hoekstra AV, Kim RJ, Small W Jr, et al. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes. Gynecol Oncol. 2009;114:273–8.PubMedCrossRef
4.
go back to reference Cragun JM, Havrilesky LJ, Calingaert B, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005;23:3668–75.PubMedCrossRef Cragun JM, Havrilesky LJ, Calingaert B, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005;23:3668–75.PubMedCrossRef
5.
go back to reference Katz LA, Andrews SJ, Fanning J. Survival after multimodality treatment for stage IIIC endometrial cancer. Am J Obstet Gynecol. 2001;184:1071–3.PubMedCrossRef Katz LA, Andrews SJ, Fanning J. Survival after multimodality treatment for stage IIIC endometrial cancer. Am J Obstet Gynecol. 2001;184:1071–3.PubMedCrossRef
6.
go back to reference Bristow RE, Zahurak ML, Alexander CJ, Zellars RC, Montz FJ. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer. 2003;13:664–72.PubMedCrossRef Bristow RE, Zahurak ML, Alexander CJ, Zellars RC, Montz FJ. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer. 2003;13:664–72.PubMedCrossRef
7.
go back to reference Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707–16.PubMedCrossRef Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707–16.PubMedCrossRef
8.
go back to reference Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373:125–36.PubMedCrossRef Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373:125–36.PubMedCrossRef
9.
go back to reference Chan JK, Cheung MK, Huh WK, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer. 2006;107:1823–30.PubMedCrossRef Chan JK, Cheung MK, Huh WK, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer. 2006;107:1823–30.PubMedCrossRef
10.
go back to reference Barrena Medel NI, Herzog TJ, Deutsch I, et al. Comparison of the prognostic significance of uterine factors and nodal status for endometrial cancer. Am J Obstet Gynecol. 2011;204:248 e1–7.PubMedCrossRef Barrena Medel NI, Herzog TJ, Deutsch I, et al. Comparison of the prognostic significance of uterine factors and nodal status for endometrial cancer. Am J Obstet Gynecol. 2011;204:248 e1–7.PubMedCrossRef
11.
go back to reference Creutzberg CL, Van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicenter randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355:1404–11.PubMedCrossRef Creutzberg CL, Van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicenter randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355:1404–11.PubMedCrossRef
12.
go back to reference Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.PubMedCrossRef Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.PubMedCrossRef
13.
go back to reference Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980;56:419–27.PubMed Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980;56:419–27.PubMed
14.
go back to reference Blake P, Swart AM, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373:137–46.PubMedCrossRef Blake P, Swart AM, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373:137–46.PubMedCrossRef
15.
go back to reference Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.PubMedCrossRef Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.PubMedCrossRef
16.
go back to reference Bendifallah S, Koskas M, Ballester M, Genin AS, Darai E, Rouzier R. The survival impact of systematic lymphadenectomy in endometrial cancer with the use of propensity score matching analysis. Am J Obstet Gynecol. 2012;206:1–11.CrossRef Bendifallah S, Koskas M, Ballester M, Genin AS, Darai E, Rouzier R. The survival impact of systematic lymphadenectomy in endometrial cancer with the use of propensity score matching analysis. Am J Obstet Gynecol. 2012;206:1–11.CrossRef
17.
go back to reference Giuntoli RL 2nd, Gerardi MA, Yemelyanova AV, et al. Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival. Int J Gynecol Cancer. 2012;22:273–9.PubMedCrossRef Giuntoli RL 2nd, Gerardi MA, Yemelyanova AV, et al. Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival. Int J Gynecol Cancer. 2012;22:273–9.PubMedCrossRef
Metadata
Title
Survival Impact of Lymphadenectomy Stratified by Nodal Metastatic Probability in Endometrial Cancer
Authors
Martin Koskas, MD
Marie Fournier, MD
Dominique Luton, MD
Emile Darai, MD
Roman Rouzier, MD
Publication date
01-07-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 7/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3589-6

Other articles of this Issue 7/2014

Annals of Surgical Oncology 7/2014 Go to the issue